Gossamer Bio, Inc.

Gossamer Bio, Inc. is a clinical-stage biopharmaceutical company focused on developing seralutinib, an inhaled therapy candidate for pulmonary arterial hypertension and related cardiopulmonary diseases. The company currently has no product sales and is funded primarily through collaboration revenue, equity financing, and other capital sources while it advances development and prepares for potential commercialization.

−352,2 %

−351,5 %

−57,7 %

2.64

2.64

— Gossamer Bio, Inc.
%
Seralutinib development0% Clinical and preclinical development of seralutinib, the company's lead inhaled therapy candidate.
Collaboration revenue100% Cost reimbursement and cost-sharing payments from the Chiesi collaboration.
License and milestone economics0% Upfront, regulatory, commercial milestone, and royalty economics tied to the Chiesi partnership.
Future product sales0% Potential direct sales of seralutinib if regulatory approval and commercialization are achieved.

Gossamer Bio does not currently sell approved products to end customers; its current revenue comes from Chiesi under a...

  • Chiesi collaboration partnerprimary

    Chiesi funds shared development and commercialization economics under the global seralutinib agreement.

  • Pulmonary arterial hypertension patientsprimary

    Future patients who may receive seralutinib if it is approved for PAH and related indications.

  • Specialist prescriberssecondary

    Pulmonologists, cardiologists, and specialty centers that would prescribe and monitor therapy.

  • Payers and reimbursement authoritiessecondary

    Insurers, government programs, and HTA bodies that determine access and pricing after approval.

The company is headquartered in the United States and its current operations are centered on U.S...

  • •United States is the core operating base and current revenue source
  • •Worldwide rights are covered by the Chiesi collaboration
  • •U.S. commercialization economics are shared with Chiesi
  • •Ex-U.S. sales would generate royalties in the mid-to-high teens
  • •EU pricing and HTA rules could affect future commercialization

The company's near-term strategy is to advance seralutinib through Phase 3 development while managing cash burn and...

01
Complete seralutinib Phase 3 developmentshort-term

Clinical success is the main value driver and prerequisite for approval and commercialization.

02
Leverage the Chiesi collaborationshort-term

The partnership reduces funding needs and shares commercialization risk.

03
Maintain financing flexibilityshort-term

The company has no product revenue and may need additional capital before approval.

04
Build a path to commercializationmedium-term

Approval would require manufacturing, distribution, and market access capabilities.

Gossamer Bio is exposed to clinical, regulatory, and financing risk because its value depends heavily on a single lead...

critical

Clinical development failure for seralutinib

The company has no approved products and depends on one lead candidate for future value creation.

Scope
Phase 3 and regulatory pathway
Materiality
high
high

Financing and liquidity risk

Current revenue is collaboration-based and may not support the cost structure before approval.

Scope
Equity, debt, or partnering needs
Materiality
high
high

Pricing and reimbursement pressure

State drug pricing rules, hospital bidding, and payer controls can reduce net realized pricing.

Scope
U.S. and ex-U.S. commercialization
Materiality
high
medium

Regulatory and HTA delays

EU HTA and national reimbursement decisions can delay or constrain market access.

Scope
Europe commercialization
Materiality
medium
medium

Trade and supply chain disruption

Tariffs, export controls, and import/export changes can affect development and commercialization logistics.

Scope
Global supply chain and manufacturing
Materiality
medium
Collaboration revenue recognition
Can create large period-to-period swings in reported revenue
Clinical trial expense timing
Directly affects operating loss and cash burn
In-process R&D expensing
Can create one-time operating expense spikes
Stock-based compensation
Affects operating expenses and non-cash dilution

Seres Therapeutics, Inc.

MCRB · Pharmaceutical Preparations

Serina Therapeutics, Inc.

SER · Pharmaceutical Preparations

TENAX THERAPEUTICS, INC.

TENX · Pharmaceutical Preparations

Upstream Bio, Inc.

UPB · Pharmaceutical Preparations

Cogent Biosciences, Inc.

COGT · Pharmaceutical Preparations

Rezolute, Inc.

RZLT · Pharmaceutical Preparations

: 28/04/2026